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Abstract
UNAIDS 90-90-90 targets and Fast-Track commitments are presented as precursors to ending the AIDS epidemic
by 2030, through effecting a 90% reduction in new HIV infections and AIDS-related deaths from 2010 levels (HIV epidemic
control). Botswana, a low to middle-income country with the third-highest HIV prevalence, and Australia, a low-prevalence
high-income country with an epidemic concentrated among men who have sex with men (MSM), have made significant strides
towards achieving the UNAIDS 90-90-90 targets. These two countries provide lessons for different epidemic settings. This
paper discusses the lessons that can be drawn from Botswana and Australia with respect to their success in HIV testing, treat-
ment, viral suppression and other HIV prevention strategies for HIV epidemic control. Botswana and Australia are on target to
achieving the 90-90-90 targets for HIV epidemic control, made possible by comprehensive HIV testing and treatment pro-
grammes in the two countries. As of 2015, 70% of all people assumed to be living with HIV had viral suppression in Botswana
and Australia. However, HIV incidence remains above one per cent in the general population in Botswana and in MSM in Aus-
tralia. The two countries have demonstrated that rapid HIV testing that is accessible and targeted at key and vulnerable popu-
lations is required in order to continue identifying new HIV infections. All citizens living with HIV in both countries are eligible
for antiretroviral therapy (ART) and viral load monitoring through government-funded programmes. Notwithstanding their suc-
cess in reducing HIV transmission to date, programmes in both countries must continue to be supported at current levels to
maintain epidemic suppression. Scaled HIV testing, linkage to care, universal ART, monitoring patients on treatment over and
above strengthened HIV prevention strategies (e.g. male circumcision and pre-exposure prophylaxis) will all continue to require
funding. The progress that Botswana and Australia have made towards meeting the 90-90-90 targets is commendable. How-
ever, in order to reduce HIV incidence significantly towards 2030, there is a need for sustained HIV testing, linkage to care
and high treatment coverage. Botswana and Australia provide useful lessons for developing countries with generalized epi-
demics and high-income countries with concentrated epidemics.
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1 | INTRODUCTION
In 2014, the Joint United Nations Programme on HIV/AIDS
(UNAIDS) set the 90-90-90 targets to be reached by 2020 in
order to end the AIDS epidemic by 2030 [1], and subse-
quently expanded them in the Fast-Track commitments drawn
from the 2016 United Nations Political Declaration [2]. The
90-90-90 HIV care cascade targets are that by 2020, 90% of
people living with HIV (PLHIV) will be diagnosed, 90% of
those diagnosed will be on antiretroviral therapy (ART), and
90% of people on treatment will achieve viral suppression.
This achievement will translate to 73% of PLHIV being virally
suppressed [1]. Achieving 90-90-90 by 2020 and scaling up to
95-95-95 by 2030 will reduce annual new HIV infections and
AIDS-related deaths by 90% compared to 2010 [3].
The 90-90-90 targets focus solely on HIV testing, ART scale-
up and viral suppression while the Fast-Track approach includes
rapid scale-up of effective prevention and treatment services as
well as zero discrimination [2]. Prevention strategies captured
in the Fast-Track approach include eliminating new infections
among children, improving access to combination HIV preven-
tion options including condom programming, pre-exposure pro-
phylaxis (PrEP), and voluntary medical male circumcision
(VMMC) in priority countries; eliminating gender inequalities
and violence; focusing on young people, and HIV-sensitive social
protection; shifting towards community-based service delivery;
investing in HIV prevention and social enablers; addressing
human rights issues for PLHIV and those at risk; and improving
universal health coverage, including treatment for tuberculosis,
cervical cancer and hepatitis B and C [2].
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Significant global scale-up of HIV testing, treatment and
viral load monitoring is required to achieve the 90-90-90 tar-
gets by 2020. In 2015, of 36.7 million PLHIV, only 57% were
diagnosed, 46% on ART, and 38% virally suppressed. With fur-
ther progress in 2016, 70% were diagnosed, 53% on treat-
ment and 44% virally suppressed [4,5]. Viral suppression is
thus significantly below the 73% target, hence a concerted
effort is still required from individual countries in order to
meet the global target.
Many countries are making significant progress towards
90-90-90 targets [4], but progress varies due to the hetero-
geneity of local epidemics and health system capacity.
Unfortunately, countries with high disease burden often
have limited resources and infrastructure. Sweden, a high-in-
come country with a centralized healthcare system and gov-
ernance and low HIV burden was the first country to
achieve the 90-90-90 targets in 2016 [6]. However, several
low-income high-HIV-burden countries are now close to
achieving the targets: Swaziland, a low-income, high-burden
country, reported 68% viral suppression among PLHIV in
2016 [5].
Botswana and Australia, with markedly different epidemics,
income levels, and HIV budgets, are close to achieving the 90-
90-90 targets with robust HIV treatment programmes for a
long time now. Botswana has a generalized HIV epidemic
while Australia has a concentrated epidemic in men who have
sex with men (MSM). Should the two countries achieve the
desired 90% reduction in new HIV infections and end AIDS-
related deaths by 2030, valuable lessons can be learned. This
commentary compares the HIV epidemics in these countries,
their progress towards achieving the 90-90-90 targets along-
side HIV incidence, and identifies lessons for HIV epidemic
control in similar settings.
2 | DISCUSSION
Botswana and Australia are on target to achieve the 90-90-90
targets for HIV epidemic control due to successful HIV testing
and treatment programmes. Their progress towards the 90-90-
90 targets and status of epidemic control is discussed below.
Lessons learned from HIV testing, ART coverage, sustained
viral suppression, financing the HIV response and monitoring
the 90-90-90 targets are explored. Table 1 summarizes key
achievements and gaps of HIV care delivery in both settings.
2.1 | 90-90-90 target status in Botswana and
Australia
The status of the 90-90-90 targets in Botswana is drawn
from a population-based survey in rural and peri-urban Bots-
wana (2013 to 2015): 83.3% (81.4% to 85.2%) of PLHIV
were diagnosed, with 87.4% (85.8% to 89.1%) on ART and
96.5% (96% to 97%) of those virally suppressed [7]. Overall,
70.2% of PLHIV were virally suppressed (Table 2). It is
important to note that these are recent estimates from an
intensive effort to enrol a representative, population-based
sample; however, some residents did not enrol (usually due
to being absent from home), and the study did not include
urban populations. Sensitivity analyses in this study [7] to
assess the potential of non-participation for the observed
90-90-90 estimates are highlighted in Table 2 (showing
lower but still relatively high 90-90-90 coverage estimates).
In 2015, modelling using Australian surveillance data and
direct observations produced estimates that 90% of PLHIV
were diagnosed, with 84% on ART and 92% of those virally
suppressed [8]. Overall, 69.5% of PLHIV in Australia were
virally suppressed (Table 2). The main difference in HIV
treatment cascades is higher HIV testing coverage in Aus-
tralia and higher ART coverage in Botswana, with overall
viral suppression of around 70% in both countries, just
below the 73% target. However, according to the 2017
UNAIDS report, Botswana has now exceeded the viral sup-
pression target, reaching 78%, while Australia is nearing the
target and is at 71% [5]. Such high levels of viral suppression
should translate into reduction in HIV incidence over time
and ultimately epidemic control.
2.2 | HIV epidemic control in Botswana and
Australia
Trends in HIV incidence and mortality can be used to track pro-
gress towards HIV epidemic control. Botswana and Australia
have reported substantial reductions in HIV-related mortality.
HIV-related mortality in Australia dropped from approximately
500 deaths in 2010 to 200 in 2015, and for Botswana from
5300 in 2010 to 3200 [16]. While reaching or exceeding the
90-90-90 targets should ensure mortality rates decrease
further, in Botswana in particular, co-infections with tuberculo-
sis, other opportunistic infections and HIV-associated cancers
[17] need to be addressed if progress is to be maintained.
In Botswana, there is no evidence that general population
HIV incidence estimates have changed substantially since
2008 [1.45% (95% confidence interval (CI) 0.66 to 2.24) in
2008 and 1.34% (95% CI 0.91 to 1.77) in 2015] [14,15,18],
although 95% confidence intervals around these estimates are
large. In Australia’s concentrated epidemic, estimates of annual
HIV incidence among MSM peaked in 2011 at 1.32% (1.03 to
1.70), declined to 0.65% (0.50 to 0.86) by 2013, before rising
to 0.89% (0.69 to 1.14) by 2015 [8].
According to UNAIDS, achieving 90-90-90 targets by 2020
(in conjunction with scale-up of HIV prevention modalities) will
be followed by HIV epidemic control in the subsequent
10 years. It is thus likely too early to assess the impact of
approaching 90-90-90 targets on incidence trends in Bots-
wana (assuming that such high levels of testing and treatment
coverage were only recently realized). In addition, other
potential reasons for persistence of high HIV incidence in
Botswana include a substantial proportion of PLHIV without
viral suppression (~30% of PLHIV) in a population with very
high-HIV prevalence, and pockets of lower testing, treatment
coverage and viral suppression in high-risk groups such as
men and young people [7,19]. In Australia, HIV incidence is
probably driven by a combination of HIV transmission from
MSM with undiagnosed HIV and delayed diagnosis in other
sub-populations [20].
Modelling suggests the greatest reductions in HIV inci-
dence from improvements in the HIV treatment cascade will
occur in regions with the greatest gaps in HIV testing and
ART coverage [21]. Despite high existing testing and ART
coverage in Botswana and Australia, efforts to address the
commitments/targets required to end AIDS by 2030
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highlighted in the Fast-Track targets, including those related
to primary prevention, should be intensified [2]. Modelling by
Scott et al. (2017) shows Australia will need to surpass the
90-90-90 targets, increase HIV testing frequency, and
increase MSM PrEP coverage and condom use to 100% in
order to achieve 80% HIV incidence reduction by 2030. The
model suggests that many countries – especially those with
low HIV prevalence – will struggle to reduce HIV incidence
by 90% by 2030 even if the UNAIDS 90-90-90 targets are
met [22]. In such cases, HIV prevention should be the focus
and this includes scaling up HIV testing, including increased
frequency of testing in key and vulnerable populations, and
promoting prevention approaches such as PrEP.
2.3 | Lessons learned
2.3.1 | HIV testing
HIV testing remains the most important step in HIV preven-
tion and care. HIV diagnostic approaches in the two countries
Table 1. Summary of key HIV care delivery achievements and gaps
Australia Botswana
Achievements Gaps Achievements Gaps
HIV testing High HIV testing
coverage
Free or low-cost
HIV testing
Point-of-care
HIV testing and
laboratory based
confirmatory
testing available
Increasing HIV
testing frequency
in risk
populations
Up-front cost
incurred for some
migrant groups i.e.
those ineligible for
government funding
Suboptimal rates of
high-frequency HIV
testing among high
risk groups
No federal
government subsidy
and limited coverage
of rapid testing
service models
Lack of home
testing options
High HIV testing
coverage
Free HIV testing
Point-of-care diagnostic
HIV testing available
Community-based
HIV testing available
Pockets of low rates of
HIV testing among
men and young people
Few HIV testing/treatment
services tailored for key
populations
(e.g. MSM, FSW)
HIV treatment &
monitoring
Government-
funded HIV
treatment
programmes
Adopted universal
treatment for all
PLHIV
High ART coverage
Routine viral load
monitoring
available
High viral
suppression
among people
on ART
Declining HIV-
related mortality
Up-front cost
incurred for some
migrant groups
Free ART for citizens,
government-funded
HIV treatment
programmes
Adopted universal
treatment for
all PLHIV
High ART coverage
Routine viral load
monitoring available
High viral suppression
among people
on ART
Declining HIV-related
mortality
Decentralized
healthcare system
with lowest facility
levels offering
HIV care
Free ART not available to
immigrants
Lack of optimal integration
of HIV treatment
services e.g. with
maternal child health,
tuberculosis, sexually
transmitted infections
HIV treatment is only
facility based and no
widespread
community-based
HIV treatment and
monitoring programmes
Programmatic
and prevention
responses
Pilot PrEP
programmes
available even
though not
accessible to
some migrants
No clear downward
trend of HIV
incidence in MSM
PrEP implementation
available but limited
to a few sites
HIV incidence remained
above 1% in 2015
Low uptake of male
circumcision
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differ. Botswana utilizes point-of-care HIV testing (POCT) with
two rapid HIV tests at clinics, hospitals, community-based
organizations, testing centres and mobile testing campaigns. In
Australia, POCT with rapid tests is used for screening; labora-
tory-based diagnostic testing is required. HIV testing in Aus-
tralia occurs through public sexual health and general
practitioners’ clinics and hospitals.
Rapid testing uptake in Australia has been modest, with lack
of medical insurance reimbursements for tests deterring use
of POCT. Strategies to enhance the reach and frequency of
HIV testing must recognize local needs, with consideration of
HIV distribution by risk populations, geography and system
capacity. Australia’s concentrated epidemic, high coverage of
primary care services in urban areas and public subsidy of
testing has meant 90% of PLHIV know their status [8]. In
Botswana, POCT delivered across clinical, programme and
community settings suits a more generalized and geographi-
cally dispersed epidemic.
Botswana and Australia have demonstrated that POCT
needs to be accessible and targeted at key and vulnerable
populations to identify new HIV infections. In Australia,
MSM, people who inject drugs (PWID) and sex workers are
key populations, while indigenous populations are considered
vulnerable [8]. In Botswana, female sex workers (FSWs),
MSM and non–citizens (illegal immigrants) are key popula-
tions, while adolescents/young people are considered vulner-
able and the testing rate is low in men [16,18]. Botswana
has expanded HIV testing beyond facility-based testing to
involve communities using community-based HIV testing
campaigns.
To progress, within countries, systems need to respond to
changes in epidemiology and political and structural environ-
ments. Identification of key and vulnerable populations and
then enhancing systems that increase HIV testing, linkage to
care and treatment in these groups is key. In Australia, recent
outbreaks of HIV among indigenous people and PWID [8] sug-
gest that new strategies are needed to reach these groups.
Similarly, in Botswana the ongoing targeting of FSWs and
increasing recognition of MSM as a key population may
require adapted models of testing to maintain and increase
Table 2. Demographics and status of UNAIDS 90-90-90 targets
Profile Australia Botswana
Demographic profile
Population 24,051,400 [9] 2,024,904 [10]
Non-citizens/immigrants 6,900,000 [9] 350,000 [10]
Gross domestic product (GDP) 1.339 trillion
USD [11]
14.39 billion USD [12]
Disease profile (HIV)
Type of HIV epidemic Concentrated Generalized
Estimated PLHIV 25,313 [8] 392,432 [13]
HIV prevalence 0.1% [8] 18.5% [14]
Annual HIV incidence 0.04% [8] 1.34% [15]
First “90” (proportion of est.
PLHIV knowing their HIV status)
90% [8] 83.3% (81.4% to 85.2%) [7]
Adjustment for non-participation by unenrolled, eligible household members:
82.8% (80.9% to 84.7%).
Standardization to Botswana nationwide census age and gender distribution:
77.8% (76.2 to 79.4)
Second “90” (proportion of
diagnosed on ART)
84% [8] 87.4% (85.8 to 89.0) [7]
Adjustment for non-participation by unenrolled, eligible household members:
87.4% (85.8 to 89.1).
Standardization to Botswana nationwide census age and gender distribution:
85.0% (83.3 to 86.8)
Third “90” (proportion of those on
ART with viral suppression)
92% [8] 96.5% (96.0 to 97.0) [7]
Adjustment for non-participation by unenrolled, eligible household members:
96.5% (96.0 to 97.0).
Standardization to Botswana nationwide census age and gender distribution:
93.9% (92.4 to 95.3)
Overall viral suppression in PLHIVa
(proportion of est. PLHIV with
viral suppression)
69.5% [8] 70.2% (67.5 to 73.0) [7]
Adjustment for non-participation by unenrolled, eligible household members:
69.8% (67.1 to 72.6).
Standardization to Botswana nationwide census age and gender distribution:
63.4% (61.6 to 65.1)
aA recent UNAIDS report categorizes Botswana as having achieved the 90-90-90 targets with 78% overall viral suppression and Australia as close
to the 73% target (68% to 72.5%) [5].
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diagnosis among PLHIV, such as the integration of HIV self-
testing into existing programmes.
2.3.2 | ART coverage
Botswana adopted the World Health Organization’s (WHO)
“treatment for all” strategy (universal ART) [22] in mid-2016
[23], whereas Australia formally implemented universal ART
policy in 2014 [24]. Interestingly, Botswana had a similarly
high estimated ART coverage (87%, vs. 84% in Australia)
among persons with diagnosed HIV infection even before
offering universal ART [7,8].
Botswana offers free ART to citizens through all levels of
its decentralized healthcare system and excludes immigrants.
In Australia, ART is provided through GPs’ clinics, sexual
health clinics, and hospitals for citizens and permanent resi-
dents, publicly funded through Australia’s universal healthcare
system with low direct costs for patients. Immigrants living
with HIV holding short-term visas are not covered, but gener-
ally access ART through compassionate programmes.
Universal ART access in Botswana and Australia – combined
with initiation of treatment in community settings – promotes
rapid ART initiation and reduced periods of infectivity. Both
healthcare systems must prepare for challenges associated
with universal ART, including drug resistance, adherence and
retention, particularly in marginalized subgroups such as immi-
grants, refugees and PWID. In Botswana, a decentralized non-
siloed healthcare system improves ART coverage; integration
of ART into maternal, newborn and child health services, and
tuberculosis treatment to reduce multiple visits to services,
could further enhance effectiveness [25].
2.3.3 | Achieving sustained viral suppression
Viral suppression rates for people on ART (defined as <400
HIV RNA copies/ml in Botswana [23] and <200 HIV RNA
copies/ml in Australia [24]) are very high and above 90% in
both countries (Table 2). Six-monthly viral load monitoring is
recommended and available for stable patients on treatment
in both countries [23,24]. As WHO guidelines specify, Aus-
tralia and Botswana have routine access to viral load monitor-
ing in their public health system, unlike many resource-limited
settings [26].
Sustained viral suppression is driven by adherence to ART
and absence of drug resistance. Enablers and disablers of
adherence should be identified and addressed. In Australia,
social/economic/cultural/patient engagement factors are asso-
ciated with suboptimal adherence while ART regimen/clinical
factors are not [27]. Community-based programmes that
enhance the continuum of care could also benefit adherence
and sustained viral suppression [28], assisting both countries
in achieving the 2030 targets.
2.3.4 | Financing the HIV response
Governments and/or donors must provide sustainable HIV
response financing. Scaled HIV testing, linkage to care, univer-
sal ART, monitoring patients on treatment, stronger condom
programming and biomedical prevention tools (e.g. VMMC,
PrEP) all require funding with strong human resources and
supply chain management.
Australia has a GDP of $1.3 trillion, while Botswana’s is
$14.3 billion (Table 2). This difference in GDP impacts on the
funding pathways for the HIV response: in Australia, the HIV
response is predominantly funded by government [24]; in
Botswana, the government funds at least 60% of its HIV
response budget, with the balance from international and pri-
vate funding [19]. A decline in international funding for Bots-
wana, because of its new upper middle-income status [29] and
an overall adverse global economic environment for aid, high-
lights the vulnerability of its HIV response [19]. Cost-benefit
assessments may identify optimal approaches to the HIV
response, but the cost relative to a country’s budget is often
critical. Innovative funding strategies, combined with improved
efficiency, will be required to ensure Botswana and similar
countries can sustain high-level HIV responses [30].
2.3.5 | Monitoring the 90-90-90 targets
Reliable data sources and standardized methodologies and
definitions are required to accurately report progress towards
the 90-90-90 targets [31], however, considerable disparities in
reporting methods exist. Use of complete population-based
datasets from clinical elements of a centralized healthcare sys-
tem to report the HIV testing and treatment cascade has
been proposed [32].
Botswana’s reported progress towards targets is based on
an ongoing population survey of adult members of 20% of
households in 30 rural and peri-urban communities (nested
within a clinical trial of interventions targeted at enhancing
HIV testing, linkage and treatment), with sensitivity analyses
including standardization to age/sex distribution from census
and HIV surveillance data [7]. Despite intensive efforts to
achieve high survey participation, these data may not be rep-
resentative of the entire population, and non-participants may
differ from survey participants in key ways. In Australia, state-
based and centralized national programmes monitor and
report HIV data [8]. Population-level data from surveillance
embedded within inter-linked rather than stand-alone health
services would be ideal, but such approaches are costly and
sometimes impractical.
3 | CONCLUSIONS
While Botswana’s and Australia’s progress towards the
UNAIDS 90-90-90 targets is commendable, HIV incidence
remains high. The hope for these two countries and others is
that sustained testing and treatment coverage will contribute
substantially toward epidemic control in the coming years. The
Fast-Track approach encourages countries to rethink and re-
emphasize primary HIV prevention, implement other strate-
gies such as PrEP, scale up HIV testing (including HIV self-
testing) and link PLHIV to care and treatment. HIV prevention
efforts need to be reinvigorated if epidemic control is to be
achieved.
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